Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioAge Labs, Inc. - Common Stock (NQ:BIOA)

21.91 +0.36 (+1.65%)
Streaming Delayed Price Updated: 1:54 PM EST, Feb 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 349,353
Open 22.50
Bid (Size) 21.84 (100)
Ask (Size) 21.99 (300)
Prev. Close 21.56
Today's Range 21.81 - 23.00
52wk Range 2.880 - 24.00
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
BioAge Labs to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
From BioAge Labs, Inc.
Via GlobeNewswire
News headline image
BioAge Announces Pricing of Upsized $115.0 Million Public Offering
From BioAge Labs, Inc.
Via GlobeNewswire

Performance

YTD
+70.8%
+70.8%
1 Month
+20.0%
+20.0%
3 Month
+143.5%
+143.5%
6 Month
+375.4%
+375.4%
1 Year
+403.8%
+403.8%

More News

Read More
News headline image
BioAge Announces Proposed Public Offering
From BioAge Labs, Inc.
Via GlobeNewswire
News headline image
BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026
From BioAge Labs, Inc.
Via GlobeNewswire
News headline image
BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with Elevated Cardiovascular Risk
From BioAge Labs, Inc.
Via GlobeNewswire
Tuesday's after hours session: top gainers and losers ↗
Via Chartmill
News headline image
2 Reasons I Wouldn't Touch BioAge Labs Stock With a 10-Foot Pole ↗
Via The Motley Fool
News headline image
BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor
From BioAge Labs, Inc.
Via GlobeNewswire
News headline image
BioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference
From BioAge Labs, Inc.
Via GlobeNewswire
News headline image
BioAge Labs to Present at Jefferies Global Healthcare Conference in London
From BioAge Labs, Inc.
Via GlobeNewswire
News headline image
BioAge Labs Inc (NASDAQ:BIOA) Reports Q3 2025 Earnings with Significant Revenue Beat ↗
Via Chartmill
News headline image
BioAge Labs Reports Third Quarter 2025 Financial Results and Provides Business Updates
From BioAge Labs, Inc.
Via GlobeNewswire
News headline image
Citigroup Says This Obesity Drugmaker's Stock Is Now a Buy ↗
Via The Motley Fool
News headline image
Could This Anti-Obesity Drug Biotech Be Poised to Soar in 2026? ↗
Via The Motley Fool
News headline image
BioAge Labs Stock Just Soared. Does It Have More Fuel to Climb Higher? ↗
Via The Motley Fool
News headline image
Here are the top movers in Thursday's session. ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
Via Benzinga
News headline image
Which stocks are moving on Thursday? ↗
Via Chartmill
News headline image
These stocks are gapping in today's session ↗
Via Chartmill
News headline image
Wondering what's happening in today's pre-market session? ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
Via Benzinga
News headline image
This Badger Meter Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday ↗
Via Benzinga
News headline image
BIOAGE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into BioAge Labs, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
BioAge Labs to Present at Upcoming Investor Conferences
From BioAge Labs, Inc.
Via GlobeNewswire
News headline image
BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor
From BioAge Labs, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is BioAge Labs, Inc. - Common Stock publicly traded?
Yes, BioAge Labs, Inc. - Common Stock is publicly traded.
What exchange does BioAge Labs, Inc. - Common Stock trade on?
BioAge Labs, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for BioAge Labs, Inc. - Common Stock?
The ticker symbol for BioAge Labs, Inc. - Common Stock is BIOA on the Nasdaq Stock Market
What is the current price of BioAge Labs, Inc. - Common Stock?
The current price of BioAge Labs, Inc. - Common Stock is 21.91
When was BioAge Labs, Inc. - Common Stock last traded?
The last trade of BioAge Labs, Inc. - Common Stock was at 02/25/26 01:54 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.